دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Few Adverse Cardiovascular Events Among Patients With Rheumatoid Arthritis Receiving Hydroxychloroquine: Are We Reassured?
Candace H. Feldman,Mark S. Link,
doi : 10.1002/art.41801
Volume 73, Issue 9 p. 1571-1573
Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis
Jose U. Scher,Alexis Ogdie,Joseph F. Merola,Christopher Ritchlin,
doi : 10.1002/art.41765
Volume 73, Issue 9 p. 1574-1578
Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis
Jérôme Avouac,Sonia Pezet,Eloïse Vandebeuque,Cindy Orvain,Virginie Gonzalez,Grégory Marin,Gaël Mouterde,Claire Daïen,Yannick Allanore,
doi : 10.1002/art.41701
Volume 73, Issue 9 p. 1579-1588
To study the potential role of semaphorins in the pathogenesis of rheumatoid arthritis (RA).
Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis
Charles Faselis,Qing Zeng-Treitler,Yan Cheng,Gail S. Kerr,David J. Nashel,Angelike P. Liappis,Amy C. Weintrob,Pamela E. Karasik,Cherinne Arundel,Denise Boehm,Michael S. Heimall,Lawrence B. Connell,Daniel D. Taub,Yijun Shao,Douglas F. Redd,Helen M. Sheriff,Sijian Zhang,Ross D. Fletcher,Gregg C. Fonarow,Hans J. Moore,Ali Ahmed
doi : 10.1002/art.41803
Volume 73, Issue 9 p. 1589-1600
Hydroxychloroquine (HCQ) may prolong the QT interval, a risk factor for torsade de pointes, a potentially fatal ventricular arrhythmia. This study was undertaken to examine the cardiovascular safety of HCQ in patients with rheumatoid arthritis (RA).
Inclusion of Synovial Tissue–Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients
Stefano Alivernini,Barbara Tolusso,Marco Gessi,Maria Rita Gigante,Alice Mannocci,Luca Petricca,Simone Perniola,Clara Di Mario,Laura Bui,Anna Laura Fedele,Annunziata Capacci,Dario Bruno,Giusy Peluso,Giuseppe La Torre,Francesco Federico,Gianfranco Ferraccioli,Elisa Gremese
doi : 10.1002/art.41726
Volume 73, Issue 9 p. 1601-1613
This study applied a synovitis score obtained during routine care from ultrasound (US)–guided biopsies of synovial tissue (ST) in patients with rheumatoid arthritis (RA) and patients with other inflammatory and noninflammatory joint diseases to identify pretreatment synovial biomarkers associated with disease characteristics, and to integrate the findings into a multiparameter nomogram for use in baseline prediction of diagnosis and treatment response in treatment-naive rheumatoid arthritis (RA) patients.
Neutrophil Phospholipase C?2 Drives Autoantibody-Induced Arthritis Through the Generation of the Inflammatory Microenvironment
Krisztina Futosi,Orsolya K?sa,Kata P. Szilveszter,Attila M?csai,
doi : 10.1002/art.41704
Volume 73, Issue 9 p. 1614-1625
Gain-of-function mutations and genome-wide association studies have linked phospholipase C?2 (PLC?2) to various inflammatory diseases, including arthritis in humans and mice. PLC?2-deficient (Plcg2–/–) mice are also protected against experimental arthritis. This study was undertaken to test how PLC?2 triggers autoantibody-induced arthritis in mice.
Stratification of Patients With Sj?gren’s Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications
Lucia Martin-Gutierrez,Junjie Peng,Nicolyn L. Thompson,George A. Robinson,Meena Naja,Hannah Peckham,WingHan Wu,Hajar J’bari,Nyarko Ahwireng,Kirsty E. Waddington,Claire M. Bradford,Giulia Varnier,Akash Gandhi,Rebecca Radmore,Vivek Gupta,David A. Isenberg,Elizabeth C. Jury,Coziana Ciurtin,
doi : 10.1002/art.41708
Volume 73, Issue 9 p. 1626-1637
Similarities in the clinical and laboratory features of primary Sj?gren’s syndrome (SS) and systemic lupus erythematosus (SLE) have led to attempts to treat patients with primary SS or SLE with similar biologic therapeutics. However, the results of many clinical trials are disappointing, and no biologic treatments are licensed for use in primary SS, while only a few biologic agents are available to treat SLE patients whose disease has remained refractory to other treatments. With the aim of improving treatment selections, this study was undertaken to identify distinct immunologic signatures in patients with primary SS and patients with SLE, using a stratification approach based on immune cell endotypes.
Association of Machine Learning–Based Predictions of Medial Knee Contact Force With Cartilage Loss Over 2.5 Years in Knee Osteoarthritis
Nicholas M. Brisson,Anthony A. Gatti,Philipp Damm,Georg N. Duda,Monica R. Maly,
doi : 10.1002/art.41735
Volume 73, Issue 9 p. 1638-1645
The relationship between in vivo knee load predictions and longitudinal cartilage changes has not been investigated. We undertook this study to develop an equation to predict the medial tibiofemoral contact force (MCF) peak during walking in persons with instrumented knee implants, and to apply this equation to determine the relationship between the predicted MCF peak and cartilage loss in patients with knee osteoarthritis (OA).
Efficacy and Safety of Diclofenac–Hyaluronate Conjugate (Diclofenac Etalhyaluronate) for Knee Osteoarthritis: A Randomized Phase III Trial in Japan
Yoshihiro Nishida,Kazuyuki Kano,Yuji Nobuoka,Takayuki Seo,
doi : 10.1002/art.41725
Volume 73, Issue 9 p. 1646-1655
To confirm the efficacy and safety of intraarticular (IA) injection of diclofenac covalently linked to hyaluronic acid (diclofenac etalhyaluronate [DF-HA]; ONO-5704/SI-613) in patients with knee osteoarthritis (OA).
Association Between Gut Microbiota and Symptomatic Hand Osteoarthritis: Data From the Xiangya Osteoarthritis Study
Jie Wei,Chenhong Zhang,Yuqing Zhang,Weiya Zhang,Michael Doherty,Tuo Yang,Guangju Zhai,Abasiama D. Obotiba,Houchen Lyu,Chao Zeng,Guanghua Lei,
doi : 10.1002/art.41729
Volume 73, Issue 9 p. 1656-1662
Systemic inflammatory factors have been implicated in symptomatic hand osteoarthritis (OA). Gut microbiome dysbiosis promotes systemic inflammation. The aim of this study was to examine the association between the gut microbiome and the presence of symptomatic hand OA in a population-based study.
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study
Laura C. Coates,Sreekumar G. Pillai,Hasan Tahir,Ivo Valter,Vinod Chandran,Hideto Kameda,Masato Okada,Lisa Kerr,Denise Alves,So Young Park,David H. Adams,Gaia Gallo,Matthew M. Hufford,Maja Hojnik,Philip J. Mease,Arthur Kavanaugh,for the SPIRIT-P3 Study Group
doi : 10.1002/art.41716
Volume 73, Issue 9 p. 1663-1672
To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open-label ixekizumab treatment.
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial
Paul A. Brogan,Barbara Arch,Helen Hickey,Jordi Anton,Este Iglesias,Eileen Baildam,Kamran Mahmood,Gavin Cleary,Elena Moraitis,Charalampia Papadopoulou,Michael W. Beresford,Phil Riley,Selcan Demir,Seza Ozen,Giovanna Culeddu,Dyfrig A. Hughes,Pavla Dolezalova,Lisa V. Hampson,John Whitehead,David Jayne,Nicola Ruperto,Catrin Tudur-Smith,Despina Eleftheriou
doi : 10.1002/art.41730
Volume 73, Issue 9 p. 1673-1682
Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT).
Eosinophil ETosis–Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis
Mineyo Fukuchi,Yosuke Kamide,Shigeharu Ueki,Yui Miyabe,Yasunori Konno,Nobuyuki Oka,Hiroki Takeuchi,Souichi Koyota,Makoto Hirokawa,Takechiyo Yamada,Rossana C. N. Melo,Peter F. Weller,Masami Taniguchi
doi : 10.1002/art.41727
Volume 73, Issue 9 p. 1683-1693
Eosinophils are tissue-dwelling immune cells. Accumulating evidence indicates that a type of cell death termed ETosis is an important cell fate involved in the pathophysiology of inflammatory diseases. Although the critical role of eosinophils in eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) is well established, the presence of eosinophil ETosis (EETosis) is poorly understood. We undertook this study to better understand the characteristics of EETosis.
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study
Federica Maritati,Francesco Peyronel,Paride Fenaroli,Francesco Pegoraro,Vieri Lastrucci,Giuseppe D. Benigno,Alessandra Palmisano,Giovanni M. Rossi,Maria L. Urban,Federico Alberici,Paolo Fraticelli,Giacomo Emmi,Massimo Corradi,Augusto Vaglio,
doi : 10.1002/art.41722
Volume 73, Issue 9 p. 1694-1702
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Environmental agents and occupational exposures may confer susceptibility to EGPA, but data are scarce. This study was undertaken to investigate the association between occupational exposures (e.g., silica, farming, asbestos, and organic solvents) and other environmental agents (e.g., smoking) and the risk of EGPA.
Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis
Rennie L. Rhee,Jiarui Lu,Kyle Bittinger,Jung-Jin Lee,Lisa M. Mattei,Antoine G. Sreih,Sherry Chou,Jonathan J. Miner,Noam A. Cohen,Brendan J. Kelly,Hongzhe Lee,Peter C. Grayson,Ronald G. Collman,Peter A. Merkel
doi : 10.1002/art.41723
Volume 73, Issue 9 p. 1703-1712
Little is known about temporal changes in nasal bacteria in granulomatosis with polyangiitis (GPA). This study was undertaken to examine longitudinal changes in the nasal microbiome in association with relapse in GPA patients.
Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study
Matthew A. Rutherford,Jennifer Scott,Maira Karabayas,Marilina Antonelou,Seerapani Gopaluni,David Gray,Joe Barrett,Silke R. Brix,Neeraj Dhaun,Stephen P. McAdoo,Rona M. Smith,Colin C. Geddes,David Jayne,Raashid Luqmani,Alan D. Salama,Mark A. Little,Neil Basu,the UK and Ireland Vasculitis Rare Disease Group (UKIVAS)
doi : 10.1002/art.41728
Volume 73, Issue 9 p. 1713-1719
COVID-19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and may be at risk of severe outcomes following COVID-19. We undertook this study to establish the risk factors for severe COVID-19 outcomes in these patients, including the impact of immunosuppressive therapies.
Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis
Micha? Rudnik,Filip Rolski,Suzana Jordan,Tonja Mertelj,Mara Stellato,Oliver Distler,Przemys?aw Blyszczuk,Gabriela Kania,
doi : 10.1002/art.41737
Volume 73, Issue 9 p. 1720-1730
Systemic sclerosis (SSc) is characterized by dysregulation of type I interferon (IFN) signaling. CD52 is known for its immunosuppressive functions in T cells. This study was undertaken to investigate the role of CD52 in monocyte adhesion and type I IFN signaling in patients with SSc.
Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort
Amber Young,Victor M. Moles,Sara Jaafar,Scott Visovatti,Suiyuan Huang,Dharshan Vummidi,Vivek Nagaraja,Vallerie McLaughlin,Dinesh Khanna,
doi : 10.1002/art.41732
Volume 73, Issue 9 p. 1731-1737
Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). This study was undertaken to assess predictive accuracies of the DETECT algorithm and the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines in SSc patients who underwent right-sided heart catheterization (RHC) for pulmonary hypertension (PH) evaluation.
Multiple Pulmonary Artery Aneurysms in Hughes-Stovin Syndrome
Nichanametla Sravani,Krishnan Nagarajan,Veer S. Negi,
doi : 10.1002/art.41759
Volume 73, Issue 9 p. 1737-1737
Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout
Xia Shen,Can Wang,Ningning Liang,Zhen Liu,Xinde Li,Zheng-Jiang Zhu,Tony R. Merriman,Nicola Dalbeth,Robert Terkeltaub,Changgui Li,Huiyong Yin,
doi : 10.1002/art.41733
Volume 73, Issue 9 p. 1738-1748
To systematically profile metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and to identify potential metabolite biomarkers to discriminate gout from asymptomatic hyperuricemia.
Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies
Samy Suissa,Karine Suissa,Marie Hudson
doi : 10.1002/art.41710
Volume 73, Issue 9 p. 1749-1757
The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares. Several observational studies have shown important reductions in mortality with allopurinol use, with wide variations in results. We undertook this review to assess the extent of bias in these studies, particularly time-related biases such as immortal time bias.
Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women
Nicola Dalbeth,Anne Horne,Borislav Mihov,Angela Stewart,Gregory D. Gamble,Tony R. Merriman,Lisa K. Stamp,Ian R. Reid,
doi : 10.1002/art.41691
Volume 73, Issue 9 p. 1758-1764
Observational studies have consistently demonstrated that serum urate level positively correlates with bone mineral density (BMD). We undertook this study to determine whether moderate hyperuricemia induced by inosine supplements influences bone turnover markers in postmenopausal women over a 6-month period.
Prophylaxis Against COVID-19 With Hydroxychloroquine and Chloroquine: Comment on the Article by Putman et al
Wei Tang,Yevgeniya Gartshteyn,Cathy Guo,Tommy Chen,Jon Giles,Anca Askanase,
doi : 10.1002/art.41742
Volume 73, Issue 9 p. 1765-1767
Reply
Michael Putman,Sebastian E. Sattui,Jeffrey A. Sparks,Jean W. Liew,Rebecca Grainger,Al? Duarte-Garc?a,
doi : 10.1002/art.41745
Volume 73, Issue 9 p. 1767-1768
Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
Mahta Mortezavi,Sujatha Menon,Kristen Lee,Jose Rivas,
doi : 10.1002/art.41806
Volume 73, Issue 9 p. 1768-1769
Reply
Jeffrey R. Curtis,Sindhu R. Johnson,Donald D. Anthony,Reuben J. Arasaratnam,Lindsey R. Baden,Ellen M. Gravallese,Anne R. Bass,Cassandra Calabrese,Rafael Harpaz,Andrew Kroger,Rebecca E. Sadun,Amy S. Turner,Eleanor Anderson Williams,Ted R. Mikuls,
doi : 10.1002/art.41805
Volume 73, Issue 9 p. 1769-1770
Are There Thresholds of Conflict of Interest With Gifts From Industry? Comment on the Article by Wayant et al
John D. FitzGerald
doi : 10.1002/art.41721
Volume 73, Issue 9 p. 1770-1770
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients Receiving Combination Therapy: Comment on the Article by Curtis et al
Rashmi Roongta,Sumantro Mondal,Alakendu Ghosh,
doi : 10.1002/art.41719
Volume 73, Issue 9 p. 1771-1771
Reply
Jeffrey R. Curtis,Elaine Karis,Priscilla K. Yen,Greg Kricorian,James B. Chung,
doi : 10.1002/art.41718
Volume 73, Issue 9 p. 1771-1772
